摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

二十碳三烯酸(5Z,8Z,14Z) | 90105-02-5

中文名称
二十碳三烯酸(5Z,8Z,14Z)
中文别名
——
英文名称
eicosa-5Z,8Z,14Z-trienoic acid
英文别名
(5Z,8Z,14Z)-icosa-5,8,14-trienoic acid
二十碳三烯酸(5Z,8Z,14Z)化学式
CAS
90105-02-5
化学式
C20H34O2
mdl
——
分子量
306.5
InChiKey
MZHLWKPZCXLYSL-IJJPYCETSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 溶解度:
    0.1 M Na2CO3:1.5 mg/ml; DMF:100 mg/ml;二甲基亚砜:100 mg/ml;乙醇:100 mg/ml

计算性质

  • 辛醇/水分配系数(LogP):
    6.7
  • 重原子数:
    22
  • 可旋转键数:
    15
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.65
  • 拓扑面积:
    37.3
  • 氢给体数:
    1
  • 氢受体数:
    2

文献信息

  • USE OF CIS-EPOXYEICOSANTRIENOIC ACIDS AND INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO REDUCE PULMONARY INFILTRATION BY NEUTROPHILS
    申请人:Hammock Bruce D.
    公开号:US20100317733A1
    公开(公告)日:2010-12-16
    It has now been discovered that inhibitors of soluble epoxide hydrolase (“sEH”) are useful in reducing the severity of or inhibiting the progression of obstructive pulmonary diseases, restrictive airway diseases, and asthma. Administering a cis-epoxyeicosantrienoic acid (“EET”) in addition to the inhibitor is at least additive, and may be synergistic, in reducing or inhibiting these conditions and diseases, as measured by reduced numbers of neutrophils present in the lung. The inhibitor of sEH may be a nucleic acid, such as a small interfering RNA.
    现在已经发现,可溶性环氧酯酶(“sEH”)的抑制剂对减轻或抑制阻塞性肺疾病、限制性气道疾病和哮喘的进展非常有用。除抑制剂外,给予顺式环氧二十碳三烯酸(“EET”)至少具有加成作用,可能对减轻或抑制这些疾病有协同作用,如通过减少肺部中中性粒细胞的数量来衡量。sEH的抑制剂可以是核酸,例如小干扰RNA。
  • US9616017B2
    申请人:——
    公开号:US9616017B2
    公开(公告)日:2017-04-11
  • [EN] COMPOSITIONS COMPRISING FATTY ACIDS AND THEIR USE<br/>[FR] COMPOSITIONS COMPRENANT DES ACIDES GRAS ET LEUR UTILISATION
    申请人:NESTEC SA
    公开号:WO2017167415A1
    公开(公告)日:2017-10-05
    The present invention relates to a composition comprising one or more fatty acid derivatives for use in promoting, supporting or optimizing one or more of the following: (i) de novo myelination; (ii) brain structure; (iii) brain connectivity; (iv) intellectual potential; (v) cognitive potential; and (vi) learning potential; (vii) cognitive functioning in an offspring of a female subject, wherein said composition is for administration to the female subject.
查看更多